Aurobindo Pharma receives EIR for sterile Drug Formulation Facility from US FDA

Aurobindo Pharma Ltd has announced that it has received the Establishment Inspection Report (EIR) from the US FDA stating their acceptance on the Company's sterile injectable formulation facility in Chitkul Village, near Hyderabad India.

This is the third successive USFDA approval for Unit-6 (the other approvals being for the formulation orals manufacturing facility and the sterile - API manufacturing facility).

The stock was trading at Rs.637, up by Rs.6.75 or 1.07%. The stock hit an intraday high of Rs.646 and low of Rs.620.55. The total traded quantity was 11137 compared to 2 week average of 23384.

Source : Equity Bulls

Keywords